Transgene’s Board of Directors Proposes the Appointment of Carol Stuckley, MBA, as New Independent Director

STRASBOURG, France--(BUSINESS WIRE)--#HBV--Regulatory News:

Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced that the Board of Directors has proposed Ms. Carol Stuckley, MBA, as an independent Director of the Company. This appointment reflects the continued evolution of Transgene’s corporate governance, which takes into account director independence, gender diversity and relevant international business experience.

Ms. Carol Stuckley brings more than 35 years of experience as a strategic and international financial executive, with proven success leading finance teams and creating shareholder value for healthcare companies.

She currently serves as a Board Director and Chairperson of the audit committee of Centessa Pharmaceuticals, plc and previously served on the board of directors of Ipsen (where she chaired the audit committee) and Epizyme, Inc.

Ms. Carol Stuckley was formerly Chief Financial Officer and Senior Vice President at HPS, which was acquired by TransUnion, Inc. Previously, Carol was Chief Financial Officer, Vice President, Finance at Galderma North America (Nestlé Skin Health S.A.). Carol started her 23-year career at Pfizer Inc., where she held multiple financial roles of increasing responsibility, and was most recently Assistant Treasurer, Vice President, Finance and Corporate Officer of Pfizer Inc.

A US citizen, Carol holds a Master of Arts Degree in Economics and an MBA in International Finance from Temple University’s Fox Business School.

Ms. Carol Stuckley will replace Mrs. Laurence Espinasse, who resigned from her position as non-independent Director. Transgene’s shareholders will vote on the nomination of Carol Stuckley at the General Shareholder Meeting to be held on May 5, 2023.

Today, the Company published the related shareholder resolution in the BALO (Bulletin des Annonces Légales Obligatoires) n° 44 of April 12, 2023 a corrigendum to the notice of meeting equivalent to the notice of meeting initially published in the BALO (Bulletin des Annonces Légales Obligatoires) n° 35 of March 22, 2023.

Following the General Meeting, subject to the adoption of the proposed resolutions, Transgene's Board of Directors will consist of 10 members, 6 of whom will be independent, benefiting from a wide range of skills relevant to the needs of the Company and respecting gender parity in accordance with the principles of French governance.

About Transgene
Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing cancer cells.
The Company’s clinical-stage programs consist of a portfolio of therapeutic vaccines and oncolytic viruses:
TG4050, the first individualized therapeutic vaccine based on the myvac® platform, TG4001 for the treatment of HPV-positive cancers, as well as TG6002, BT-001 and TG6050, three oncolytic viruses based on the Invir.IO® viral backbone.
With Transgene’s myvac® platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The myvac® approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC.
With its proprietary platform Invir.IO®, Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses. Transgene has an ongoing Invir.IO® collaboration with AstraZeneca. Additional information about Transgene is available at: www.transgene.fr
Follow us on Twitter: @TransgeneSA

Disclaimer
This press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. The occurrence of any of these risks could have a significant negative outcome for the Company’s activities, perspectives, financial situation, results, regulatory authorities’ agreement with development phases, and development. The Company’s ability to commercialize its products depends on but is not limited to the following factors: positive pre-clinical data may not be predictive of human clinical results, the success of clinical studies, the ability to obtain financing and/or partnerships for product manufacturing, development and commercialization, and marketing approval by government regulatory authorities. For a discussion of risks and uncertainties which could cause the Company’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Universal Registration Document, available on the AMF website (http://www.amf-france.org) or on Transgene’s website (www.transgene.fr). Forward-looking statements speak only as of the date on which they are made, and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.

Transgene:
Lucie Larguier
+33 (0)3 88 27 91 04
investorrelations@transgene.fr

Media:
MEDiSTRAVA Consulting
David Dible/Sylvie Berrebi/George Underwood
+44 (0)203 928 6900
transgene@medistrava.com